JP7147030B2 - 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 - Google Patents

抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 Download PDF

Info

Publication number
JP7147030B2
JP7147030B2 JP2021151709A JP2021151709A JP7147030B2 JP 7147030 B2 JP7147030 B2 JP 7147030B2 JP 2021151709 A JP2021151709 A JP 2021151709A JP 2021151709 A JP2021151709 A JP 2021151709A JP 7147030 B2 JP7147030 B2 JP 7147030B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
variable region
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021151709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022051553A (ja
JP2022051553A5 (https=
Inventor
佑理 井川
有生 大倉
暁彦 溝呂木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2022051553A publication Critical patent/JP2022051553A/ja
Publication of JP2022051553A5 publication Critical patent/JP2022051553A5/ja
Priority to JP2022139889A priority Critical patent/JP7840234B2/ja
Application granted granted Critical
Publication of JP7147030B2 publication Critical patent/JP7147030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021151709A 2020-09-18 2021-09-17 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 Active JP7147030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022139889A JP7840234B2 (ja) 2020-09-18 2022-09-02 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020157873 2020-09-18
JP2020157873 2020-09-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139889A Division JP7840234B2 (ja) 2020-09-18 2022-09-02 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Publications (3)

Publication Number Publication Date
JP2022051553A JP2022051553A (ja) 2022-03-31
JP2022051553A5 JP2022051553A5 (https=) 2022-06-01
JP7147030B2 true JP7147030B2 (ja) 2022-10-04

Family

ID=80739984

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021151709A Active JP7147030B2 (ja) 2020-09-18 2021-09-17 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用
JP2022139889A Active JP7840234B2 (ja) 2020-09-18 2022-09-02 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022139889A Active JP7840234B2 (ja) 2020-09-18 2022-09-02 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Country Status (16)

Country Link
US (2) US11739153B2 (https=)
EP (1) EP4214236A4 (https=)
JP (2) JP7147030B2 (https=)
KR (2) KR20230116942A (https=)
CN (3) CN117801114A (https=)
AR (1) AR123537A1 (https=)
AU (2) AU2021343008B2 (https=)
CA (1) CA3192661A1 (https=)
CL (1) CL2023000765A1 (https=)
CO (1) CO2023003681A2 (https=)
CR (1) CR20230166A (https=)
IL (1) IL301326A (https=)
MX (1) MX2023002191A (https=)
PE (1) PE20231208A1 (https=)
TW (2) TW202402804A (https=)
WO (1) WO2022059766A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022172276A (ja) * 2020-09-18 2022-11-15 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153847A1 (en) * 2019-04-01 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
US20240400693A1 (en) * 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Drug formulation of anti-hla-dq2.5 antibody
TW202333781A (zh) * 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
WO2026044027A1 (en) * 2024-08-20 2026-02-26 Victor Raso Major histocompatibility complex peptides as therapeutic targets for autoimmune diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069993A1 (en) 2017-10-03 2019-04-11 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 ANTIBODIES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
IL158342A0 (en) 2001-04-12 2004-05-12 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
EP2249801A2 (en) 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
AU2013204429B9 (en) 2008-11-30 2017-01-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
WO2010141658A1 (en) 2009-06-04 2010-12-09 The Regent Of The University Of Colorado Therapeutic compositions and methods for the prevention of autoimmune diseases
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CN104011207B (zh) * 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2016202805A2 (en) 2015-06-15 2016-12-22 Consejo Superior De Investigaciones Científicas (Csic) Targeting of prolamin by rnai in bread wheat
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP7162607B2 (ja) * 2017-02-27 2022-10-28 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５／８抗体およびセリアック病の治療のためのその使用
GB201802338D0 (en) * 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
US20220153847A1 (en) 2019-04-01 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
JP7147030B2 (ja) 2020-09-18 2022-10-04 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069993A1 (en) 2017-10-03 2019-04-11 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 ANTIBODIES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Clin. Invest., 2006年，Vol.116, No.8，p.2226-2236
Plant J., 2015年，Vol.82, No.5，p.794-805

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022172276A (ja) * 2020-09-18 2022-11-15 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用
JP7840234B2 (ja) 2020-09-18 2026-04-03 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Also Published As

Publication number Publication date
AR123537A1 (es) 2022-12-14
CA3192661A1 (en) 2022-03-24
JP2022051553A (ja) 2022-03-31
AU2021343008B2 (en) 2025-11-13
JP7840234B2 (ja) 2026-04-03
CN117801115A (zh) 2024-04-02
EP4214236A1 (en) 2023-07-26
US20220089743A1 (en) 2022-03-24
CN116096757A (zh) 2023-05-09
WO2022059766A1 (en) 2022-03-24
TWI820484B (zh) 2023-11-01
US11739153B2 (en) 2023-08-29
KR102559128B1 (ko) 2023-07-24
US20230357408A1 (en) 2023-11-09
MX2023002191A (es) 2023-03-03
AU2021343008A1 (en) 2023-06-01
AU2026200463A1 (en) 2026-02-12
EP4214236A4 (en) 2024-10-30
KR20220153469A (ko) 2022-11-18
IL301326A (en) 2023-05-01
CN117801114A (zh) 2024-04-02
JP2022172276A (ja) 2022-11-15
AU2021343008A9 (en) 2024-10-10
CO2023003681A2 (es) 2023-04-05
PE20231208A1 (es) 2023-08-17
TW202229345A (zh) 2022-08-01
TW202402804A (zh) 2024-01-16
KR20230116942A (ko) 2023-08-04
CL2023000765A1 (es) 2023-11-03
CR20230166A (es) 2023-05-31
CN116096757B (zh) 2024-01-12

Similar Documents

Publication Publication Date Title
JP7147030B2 (ja) 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用
JP7689495B2 (ja) 抗ｈｌａ－ｄｑ２．５抗体
WO2023058705A1 (ja) 抗ｈｌａ－ｄｑ２．５抗体の製剤
JP7220335B1 (ja) 抗ｈｌａ－ｄｑ２．５抗体の製剤
HK40101674A (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40101688A (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40084713A (en) Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
HK40084713B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
EA052398B1 (ru) Антитело к hla-dq2.5 и его применение для лечения глютеновой энтеропатии
HK40106801A (zh) 抗hla-dq2.5抗体的药物制剂
HK40062978B (zh) 抗hla-dq2.5抗体
HK40062978A (en) Anti-hla-dq2.5 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220524

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220921

R150 Certificate of patent or registration of utility model

Ref document number: 7147030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150